| 16.87 0.02 (0.12%) | 07-07 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.83 | 1-year : | 23.16 |
| Resists | First : | 16.97 | Second : | 19.83 |
| Pivot price | 16.83  |
|||
| Supports | First : | 16.49 | Second : | 16.2 |
| MAs | MA(5) : | 16.85 | MA(20) : | 16.84 |
| MA(100) : | 12.27 |
MA(250) : | 9.17 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 83.3 | D(3) : | 83.3 |
| RSI | RSI(14): 66.7 | |||
| 52-week | High : | 16.97 | Low : | 4.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VECT ] has closed below upper band by 47.4%. Bollinger Bands are 78% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 16.89 - 16.97 | 16.97 - 17.04 |
| Low: | 16.61 - 16.73 | 16.73 - 16.82 |
| Close: | 16.69 - 16.86 | 16.86 - 17 |
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Thu, 29 Jun 2023
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares - Yahoo Finance
Mon, 22 May 2023
Ironwood bulks up on digestive therapies with $1.15 bln VectivBio buy - Reuters.com
Mon, 22 May 2023
Ironwood Scoops Up Gastrointestinal Diseases Player For $1B - Markets Insider
Mon, 22 May 2023
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel ... - Business Wire
Mon, 22 May 2023
Latham Watkins Advises Ironwood Pharmaceuticals in Acquisition of VectivBio - Latham & Watkins LLP
Mon, 22 May 2023
VectivBio Holding To Be Acquired By Ironwood Pharmaceuticals For $1 Billion | News & Events | Goodwin - Goodwin Procter
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 83.8 (%) |
| Shares Short | 78 (K) |
| Shares Short P.Month | 580 (K) |
| EPS | -2.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.4 |
| Profit Margin | 0 % |
| Operating Margin | -294.6 % |
| Return on Assets (ttm) | -25.9 % |
| Return on Equity (ttm) | -57 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.43 |
| Sales Per Share | 0.43 |
| EBITDA (p.s.) | -1.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -8.03 |
| PEG Ratio | 0 |
| Price to Book value | 4.95 |
| Price to Sales | 38.71 |
| Price to Cash Flow | -18.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|